Titre : Pharmacoéconomie

Pharmacoéconomie : Questions médicales fréquentes

Termes MeSH sélectionnés :

Robotics
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Pharmacoéconomie : Questions médicales les plus fréquentes", "headline": "Pharmacoéconomie : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Pharmacoéconomie : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-05", "dateModified": "2025-04-01", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Pharmacoéconomie" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Économie", "url": "https://questionsmedicales.fr/mesh/D004467", "about": { "@type": "MedicalCondition", "name": "Économie", "code": { "@type": "MedicalCode", "code": "D004467", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.219" } } }, "about": { "@type": "MedicalCondition", "name": "Pharmacoéconomie", "alternateName": "Economics, Pharmaceutical", "code": { "@type": "MedicalCode", "code": "D017850", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Michele B Kaufman", "url": "https://questionsmedicales.fr/author/Michele%20B%20Kaufman", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Peivand Bastani", "url": "https://questionsmedicales.fr/author/Peivand%20Bastani", "affiliation": { "@type": "Organization", "name": "Health Human Resources Research Center, School of Health Management and Medical Informatics, Shiraz University of Medical Sciences, Shiraz, Iran." } }, { "@type": "Person", "name": "Zahra Dehghan", "url": "https://questionsmedicales.fr/author/Zahra%20Dehghan", "affiliation": { "@type": "Organization", "name": "Vice-Chancellery for Food and Drug, Shiraz University of Medical Sciences, Shiraz, Iran." } }, { "@type": "Person", "name": "Seyyed Mansoor Kashfi", "url": "https://questionsmedicales.fr/author/Seyyed%20Mansoor%20Kashfi", "affiliation": { "@type": "Organization", "name": "Department of Public Health, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran." } }, { "@type": "Person", "name": "Hesam Dorosti", "url": "https://questionsmedicales.fr/author/Hesam%20Dorosti", "affiliation": { "@type": "Organization", "name": "Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Interactive mirrOring Games wIth sOCial rObot (IOGIOCO): a pilot study on the use of intransitive gestures in a sample of Italian preschool children with autism spectrum disorder.", "datePublished": "2024-06-28", "url": "https://questionsmedicales.fr/article/39006819", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpsyt.2024.1356331" } }, { "@type": "ScholarlyArticle", "name": "Minimising warm ischaemia time during robot-assisted partial nephrectomy. A video-based assessment of tumour excision, kidney reconstruction and intermediate time.", "datePublished": "2024-06-19", "url": "https://questionsmedicales.fr/article/38896070", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2340/sju.v59.40397" } }, { "@type": "ScholarlyArticle", "name": "Membranous urethral length is the single independent predictor of urinary continence recovery at 12 months following Retzius-sparing robot-assisted radical prostatectomy.", "datePublished": "2024-05-29", "url": "https://questionsmedicales.fr/article/38809307", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11701-024-01986-8" } }, { "@type": "ScholarlyArticle", "name": "Enhanced recovery after surgery day surgery for MAKO® robotic-arm assisted TKA; better outcome for patients, improved efficiency for hospitals.", "datePublished": "2024-05-11", "url": "https://questionsmedicales.fr/article/38800590", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jor.2024.05.013" } }, { "@type": "ScholarlyArticle", "name": "Safety and Efficacy of a Novel Miniaturized Robotic Assisted Surgery System in Colectomy: A Prospective, Investigational Device Exemption Clinical Study Using the IDEAL Framework.", "datePublished": "2024-04-23", "url": "https://questionsmedicales.fr/article/38653496", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/DCR.0000000000003249" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Organisations et économie des soins de santé", "item": "https://questionsmedicales.fr/mesh/D004472" }, { "@type": "ListItem", "position": 3, "name": "Économie", "item": "https://questionsmedicales.fr/mesh/D004467" }, { "@type": "ListItem", "position": 4, "name": "Pharmacoéconomie", "item": "https://questionsmedicales.fr/mesh/D017850" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Pharmacoéconomie - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Pharmacoéconomie", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Pharmacoéconomie", "description": "Comment évaluer le coût d'un traitement médicamenteux ?\nQu'est-ce qu'une analyse coût-efficacité ?\nQuels sont les indicateurs de performance en pharmacoéconomie ?\nComment mesurer l'impact économique d'un nouveau médicament ?\nQu'est-ce qu'une étude de faisabilité en pharmacoéconomie ?", "url": "https://questionsmedicales.fr/mesh/D017850?mesh_terms=Robotics&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Pharmacoéconomie", "description": "Quels symptômes peuvent influencer le coût des traitements ?\nComment les effets secondaires impactent-ils les coûts ?\nLes symptômes psychologiques influencent-ils les coûts ?\nComment évaluer le coût des symptômes aigus ?\nLes symptômes liés à une maladie chronique augmentent-ils les coûts ?", "url": "https://questionsmedicales.fr/mesh/D017850?mesh_terms=Robotics&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Pharmacoéconomie", "description": "Comment la prévention influence-t-elle les coûts de santé ?\nQuels programmes de prévention sont les plus rentables ?\nComment évaluer le coût des interventions préventives ?\nLes campagnes de sensibilisation sont-elles rentables ?\nQuel est le rôle des politiques de santé dans la prévention ?", "url": "https://questionsmedicales.fr/mesh/D017850?mesh_terms=Robotics&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Pharmacoéconomie", "description": "Comment comparer les coûts des différents traitements ?\nQuels facteurs influencent le coût des médicaments ?\nQu'est-ce qu'un médicament générique ?\nComment les politiques de santé influencent-elles les coûts des traitements ?\nQuel est l'impact des traitements innovants sur les coûts ?", "url": "https://questionsmedicales.fr/mesh/D017850?mesh_terms=Robotics&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Pharmacoéconomie", "description": "Comment les complications augmentent-elles les coûts ?\nQuelles complications sont les plus coûteuses ?\nComment évaluer le coût des complications ?\nLes complications peuvent-elles être évitées ?\nQuel est l'impact des complications sur la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D017850?mesh_terms=Robotics&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Pharmacoéconomie", "description": "Quels facteurs de risque augmentent les coûts de santé ?\nComment évaluer l'impact économique des facteurs de risque ?\nLes facteurs de risque environnementaux influencent-ils les coûts ?\nComment réduire les coûts liés aux facteurs de risque ?\nQuel est le rôle de l'éducation dans la gestion des facteurs de risque ?", "url": "https://questionsmedicales.fr/mesh/D017850?mesh_terms=Robotics&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer le coût d'un traitement médicamenteux ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le coût est évalué en tenant compte des prix des médicaments, des frais de santé associés et des résultats cliniques." } }, { "@type": "Question", "name": "Qu'est-ce qu'une analyse coût-efficacité ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "C'est une méthode qui compare les coûts et les effets d'interventions pour déterminer la meilleure option." } }, { "@type": "Question", "name": "Quels sont les indicateurs de performance en pharmacoéconomie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les indicateurs incluent le coût par qualité de vie ajustée (QALY) et le coût par an de vie gagné." } }, { "@type": "Question", "name": "Comment mesurer l'impact économique d'un nouveau médicament ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "On mesure l'impact en comparant les coûts et les bénéfices par rapport aux traitements existants." } }, { "@type": "Question", "name": "Qu'est-ce qu'une étude de faisabilité en pharmacoéconomie ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "C'est une évaluation préliminaire pour déterminer si une étude plus approfondie est justifiée." } }, { "@type": "Question", "name": "Quels symptômes peuvent influencer le coût des traitements ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes chroniques ou complexes peuvent nécessiter des traitements plus coûteux et prolongés." } }, { "@type": "Question", "name": "Comment les effets secondaires impactent-ils les coûts ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent entraîner des hospitalisations et des traitements supplémentaires, augmentant les coûts." } }, { "@type": "Question", "name": "Les symptômes psychologiques influencent-ils les coûts ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les troubles psychologiques peuvent nécessiter des traitements prolongés et coûteux." } }, { "@type": "Question", "name": "Comment évaluer le coût des symptômes aigus ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Le coût des symptômes aigus inclut les consultations, les traitements d'urgence et les hospitalisations." } }, { "@type": "Question", "name": "Les symptômes liés à une maladie chronique augmentent-ils les coûts ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies chroniques nécessitent souvent des traitements réguliers, augmentant les coûts globaux." } }, { "@type": "Question", "name": "Comment la prévention influence-t-elle les coûts de santé ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention réduit les maladies et les traitements nécessaires, diminuant ainsi les coûts globaux." } }, { "@type": "Question", "name": "Quels programmes de prévention sont les plus rentables ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les programmes de vaccination et de dépistage précoce sont souvent les plus rentables en termes de coûts." } }, { "@type": "Question", "name": "Comment évaluer le coût des interventions préventives ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "On évalue le coût en comparant les dépenses de prévention aux économies réalisées sur les traitements futurs." } }, { "@type": "Question", "name": "Les campagnes de sensibilisation sont-elles rentables ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent réduire les coûts de santé en augmentant la prévention et en diminuant les maladies." } }, { "@type": "Question", "name": "Quel est le rôle des politiques de santé dans la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les politiques de santé soutiennent la prévention par des financements et des programmes ciblés." } }, { "@type": "Question", "name": "Comment comparer les coûts des différents traitements ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "On compare les coûts directs, indirects et les résultats cliniques pour chaque traitement." } }, { "@type": "Question", "name": "Quels facteurs influencent le coût des médicaments ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent la recherche et développement, la production, la distribution et la demande." } }, { "@type": "Question", "name": "Qu'est-ce qu'un médicament générique ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Un médicament générique est une version moins coûteuse d'un médicament de marque, avec la même efficacité." } }, { "@type": "Question", "name": "Comment les politiques de santé influencent-elles les coûts des traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les politiques peuvent réguler les prix, influencer l'accès et déterminer le remboursement des traitements." } }, { "@type": "Question", "name": "Quel est l'impact des traitements innovants sur les coûts ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements innovants peuvent être coûteux, mais peuvent offrir des bénéfices cliniques significatifs." } }, { "@type": "Question", "name": "Comment les complications augmentent-elles les coûts ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications nécessitent souvent des traitements supplémentaires, des hospitalisations et des soins prolongés." } }, { "@type": "Question", "name": "Quelles complications sont les plus coûteuses ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Les complications liées aux maladies chroniques, comme le diabète, sont souvent les plus coûteuses." } }, { "@type": "Question", "name": "Comment évaluer le coût des complications ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "On évalue le coût en tenant compte des traitements, des hospitalisations et des pertes de productivité." } }, { "@type": "Question", "name": "Les complications peuvent-elles être évitées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, de nombreuses complications peuvent être évitées par une gestion appropriée des maladies et des traitements." } }, { "@type": "Question", "name": "Quel est l'impact des complications sur la qualité de vie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent réduire la qualité de vie en entraînant des douleurs, des limitations et des coûts élevés." } }, { "@type": "Question", "name": "Quels facteurs de risque augmentent les coûts de santé ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs de risque comme l'obésité et le tabagisme entraînent des maladies coûteuses à traiter." } }, { "@type": "Question", "name": "Comment évaluer l'impact économique des facteurs de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "On évalue l'impact en analysant les coûts des traitements associés aux maladies causées par ces facteurs." } }, { "@type": "Question", "name": "Les facteurs de risque environnementaux influencent-ils les coûts ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les facteurs environnementaux peuvent augmenter les maladies et donc les coûts de santé associés." } }, { "@type": "Question", "name": "Comment réduire les coûts liés aux facteurs de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "On peut réduire les coûts par des programmes de prévention ciblés et des interventions communautaires." } }, { "@type": "Question", "name": "Quel est le rôle de l'éducation dans la gestion des facteurs de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "L'éducation aide à sensibiliser et à modifier les comportements, réduisant ainsi les coûts de santé futurs." } } ] } ] }

Sources (10000 au total)

Interactive mirrOring Games wIth sOCial rObot (IOGIOCO): a pilot study on the use of intransitive gestures in a sample of Italian preschool children with autism spectrum disorder.

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by persistent deficits in social communication, social interaction, and restricted behaviors. The importance of early inte... We developed a training protocol using the humanoid robot NAO, called IOGIOCO (Interactive mirroring Games wIth sOCial rObot), based on the use of intransitive gestures embedded in naturalistic dialog... We demonstrated the tolerability of the protocol. We found that one group (n=4, males and 2 females) reached the training level, while another and group (n=6 males) remained at a familiarization level... While current results will need a Randomized Controlled Trial to be confirmed, the present work sets an important milestone in using social robots for ASD treatment, aimed at impacting social and comm...

Minimising warm ischaemia time during robot-assisted partial nephrectomy. A video-based assessment of tumour excision, kidney reconstruction and intermediate time.

Surgical video review is an emerging tool for assessing patient outcomes, especially in complex surgeries such as robot-assisted partial nephrectomy (RAPN). Assessing and measuring warm ischaemia time... We evaluated 32 surgical video recordings from patients undergoing RAPN and measured WIT, ExcT, RecT and IntT with a stopwatch. Factors such as tumour characteristics and surgeon experience were also ... We recorded a median WIT of 1,048 s (17 min and 28 s). The median of ExcT, RecT and IntT was 398 s (37.1% of WIT), 518 s (46.7% of WIT) and 180 s (16.2% of WIT), respectively. We found a significant c... Tumour morphology influences all surgical times, and surgeon experience influences only ExcT. We observed a short RecT during RAPN though at the cost of increased ExcT, and we believe that improving s...

Membranous urethral length is the single independent predictor of urinary continence recovery at 12 months following Retzius-sparing robot-assisted radical prostatectomy.

The influence of anatomical parameters on urinary continence (UC) after Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) remains uncharted. Our objective was to evaluate their associatio...

Enhanced recovery after surgery day surgery for MAKO® robotic-arm assisted TKA; better outcome for patients, improved efficiency for hospitals.

Robotic-assisted Total Knee Arthroplasty (TKA) was designed to improve implant position accuracy by providing surgeons with real-time intra-operative data to tailor the operation to the patient. Propo... All patients who had undergone unilateral MAKO® ERAS Day Surgery TKA from August 2020 to July 2021 were prospectively followed up and matched to patients who underwent conventional ERAS Day Surgery TK... 42 patients underwent MAKO® ERAS Day surgery TKA and were matched to 42 patients who underwent conventional ERAS Day surgery TKA. The study found that despite the longer surgical duration, LOS was com... ERAS Day Surgery protocol can significantly reduce the LOS of patient undergoing MAKO® Robotic-arm Assisted TKA, conferring cost savings and making it a valid option for patients....

Safety and Efficacy of a Novel Miniaturized Robotic Assisted Surgery System in Colectomy: A Prospective, Investigational Device Exemption Clinical Study Using the IDEAL Framework.

Robotics has increased rates of minimally invasive surgery, with distinct advantages over open surgery. However, current commercially available robotic platforms have device and system issues that lim... To demonstrate the safety and efficacy of a novel miniaturized robotic assisted surgery device in colectomy.... Prospective, Investigational Device Exemption clinical study following the idea, development, exploration, assessment, and long-term follow-up (IDEAL) framework (Stage 2b, exploration).... Three centers with high-volume robotic colorectal cases and surgeons.... Patients scheduled for a right or left colectomy for benign or malignant disease.... Colectomy with the novel miniaturized robotic assisted surgery device.... For safety, intraoperative and device-related adverse events and 30-day morbidity. For efficacy, successful completion of pre-defined procedural steps without conversion.... Thirty patients (13 female, 17 male) were analyzed. The mean age was 59.4 (SD 13.4) years. Seventy percent (n = 21) were overweight/obese and 53.3% (n = 16) had prior abdominal surgery. Forty percent ... Single arm study, short-term follow-up.... This first clinical study of a novel miniaturized robotic-assisted surgery device along the IDEAL framework demonstrated it was safe and effective. Given this success, further assessment and long-term...

Lower Intraoperative and Immediate Postoperative Complications in Robotic Versus Conventional Primary Total Hip Arthroplasty: A Retrospective Cohort Analysis of Over 360,000 Patients.

Although a trend of an improved alignment with robotic total hip arthroplasty (THA) over conventional methods has surfaced from recent series, it is unknown whether these results translate into meanin... Records were extracted from 2016-2019 from the National Inpatient Sample (NIS) database Healthcare Cost and Utilization Project which is the largest in-patient database in the United States. From 367,... Demographic distributions between robotic and conventional THA groups displayed similar age and sex characteristics. Shorter mean lengths of stay (1.87 days) were seen in robotic THA versus convention... Evidence has emerged from our results to support more routine adaptation of the robotic option of performing a THA. These can be based on lower local, systemic, and mechanical complications as demonst...

The Combined Effect of Robot Assisted Therapy and Activities of Daily Living Training on Upper Limb Recovery in Persons with Subacute Stroke: A Randomized Controlled Trial.

To evaluate the effectiveness of robot-assisted therapy (RAT) followed by activities of daily living (ADL) training in comparison with conventional rehabilitation therapy (CRT) and ADL training in ind... A single-blind, two-arm, parallel-group, open-level, randomized controlled trial.... A tertiary care teaching hospital in India PARTICIPANTS: Forty-four persons (n=44) with first-ever stroke (in subacute stage) were enrolled from August 2021, to July, 2023.... Participants in the RAT group (n=22) received RAT for 30 minutes, followed by ADL training for 30 minutes. In contrast, participants in the CRT group (n=22) received CRT (30 minutes) followed by ADL t... Primary outcome: Motor domain score of the Fugl-Meyer Assessment scale for upper extremity (FMA-UE).... the other domains scores of FMA-UE (UL -sensation, -joint motions, -joint pain); Modified Ashworth Scale (MAS) (spasticity); hand-function (HF) and ADL-domain scores of the stroke impact scale (SIS); ... Persons who received RAT and ADL training reported significant improvement (p<0.05) in UL motor function [Mean difference (MD)=3.54;(95% confidence interval (CI): 1.28 to 5.79)], UL passive joint moti... The findings indicate that RAT followed by ADL training is more effective than CRT followed by ADL training in motor improvement, hand functions, ADL, and QOL at 12 weeks....

Comparison of Short-term and Three-year Oncological Outcomes Between Robotic and Laparoscopic Gastrectomy for Gastric Cancer: A Large Multi-center Cohort Study.

To compare the short- and long-term outcomes between robotic gastrectomy (RG) and laparoscopic gastrectomy (LG) for gastric cancer.... The clinical outcomes of RG over LG have not yet been effectively demonstrated.... This retrospective cohort study included 3,599 patients with gastric cancer who underwent radical gastrectomy at eight high-volume hospitals in China from August 2016 to June 2019. Propensity score ma... After 1:1 PSM, 1034 pairs of patients were enrolled in a balanced cohort for further analysis. The 3-year DFS in the RG and LG was 83.7% and 83.1% (P=0.745), respectively, and the 3-year overall survi... For resectable gastric cancer, including advanced cases, RG is a safe approach with comparable 3-year oncological outcomes to LG when performed by experienced surgeons....

Case report: Robotically visualized and biopsy-confirmed peritoneal carcinomatosis as initial identification of metastatic prostate adenocarcinoma in a patient with a history of prostatic urethral lift.

Peritoneal carcinomatosis is a particularly rare presentation of prostate cancer. Here we report a rare clinical case of surgically identified peritoneal carcinomatosis at the time of a planned roboti... A 72-year-old man, with a history of urinary retention managed with tamsulosin, presented to his local urologist. Prostatic urethral lift procedures were performed for symptom management. After a defi... Our patient, diagnosed with peritoneal carcinomatosis during a planned RALP, highlights the importance of vigilant laparoscopic exam prior to this prostatectomy. Multidisciplinary discussion is crucia...